Product Update Johnson & Johnson Medical Ltd Surgicel Haemostat Fabrics ELS041, ELS064, ELS065 and ELS115 (ICN 3177)

• The product pack change size with Surgicel haemostat fabrics is continuing.
• Four products will be changing from a pack of 12 to a pack of 10:
  • ELS041, ELS064, ELS065 and ELS115.
• We have now been advised that they will be phased in from February 2027.
• The four products will continue to be available until further notice.
• See our Downloads ▼ section to access the product listing for further information on the affected product codes.
• We will update this ICN as soon as we have further information on the transition.
• If you have any further questions, please contact your local NHS Supply Chain Customer Services Advisor.

Change:

• The supplier Johnson & Johnson Medical Ltd has informed us of a product update with its Surgicel haemostat fabrics.
• Four products are in the process of changing from a pack of 12 to a pack of 10:
  • ELS041, ELS064, ELS065 and ELS115.
• According to the launch materials for the new framework (Wound Closure 2026), the products were expected to be replaced by packs of 10 at launch (19 January 2026), this is now no longer the case.
• We have now been advised that they will be phased in throughout 2026, with no specific date for each product.
• The existing four product codes will therefore continue to be available until further notice
• These products will remain in stock.
• The new products will have replacement product codes.

Impact:

• See our Downloads section for further information on the affected product codes.
• Customers can continue to purchase the existing four products until further notice.
• The replacement products are currently unavailable and not visible in our online catalogue.

Next Steps:   

• Customers are advised to log into our website to view the potential indirect alternative products.
• If you have any further questions, please contact your local NHS Supply Chain Customer Services Advisor.

Please note that due to the clinical nature of these alternative products, we advise you to consult your own clinical experts to ensure suitability for your organisations use of these products.